HK1202551A1 - 作為 抑制劑的四氫-喹唑啉酮衍生物 - Google Patents
作為 抑制劑的四氫-喹唑啉酮衍生物Info
- Publication number
- HK1202551A1 HK1202551A1 HK15103292.2A HK15103292A HK1202551A1 HK 1202551 A1 HK1202551 A1 HK 1202551A1 HK 15103292 A HK15103292 A HK 15103292A HK 1202551 A1 HK1202551 A1 HK 1202551A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- tank
- parp
- tetrahydro
- quinazolinone derivatives
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12000841 | 2012-02-09 | ||
| PCT/EP2013/000078 WO2013117288A1 (en) | 2012-02-09 | 2013-01-14 | Tetrahydro-quinazolinone derivatives as tank and parp inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1202551A1 true HK1202551A1 (zh) | 2015-10-02 |
Family
ID=47628092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15103292.2A HK1202551A1 (zh) | 2012-02-09 | 2015-04-01 | 作為 抑制劑的四氫-喹唑啉酮衍生物 |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US9339503B2 (zh) |
| EP (1) | EP2812323B1 (zh) |
| JP (1) | JP6116592B2 (zh) |
| KR (1) | KR20140121477A (zh) |
| CN (1) | CN104093714B (zh) |
| AR (1) | AR089944A1 (zh) |
| AU (1) | AU2013218357B2 (zh) |
| BR (1) | BR112014019357A8 (zh) |
| CA (1) | CA2863991C (zh) |
| CL (1) | CL2014002097A1 (zh) |
| CO (1) | CO7020919A2 (zh) |
| DK (1) | DK2812323T3 (zh) |
| EA (1) | EA026611B1 (zh) |
| EC (1) | ECSP14017586A (zh) |
| ES (1) | ES2579980T3 (zh) |
| HK (1) | HK1202551A1 (zh) |
| HR (1) | HRP20160735T1 (zh) |
| HU (1) | HUE029717T2 (zh) |
| IL (1) | IL233984A (zh) |
| MX (1) | MX349736B (zh) |
| NZ (1) | NZ630170A (zh) |
| PE (1) | PE20141823A1 (zh) |
| PH (1) | PH12014501581A1 (zh) |
| PL (1) | PL2812323T3 (zh) |
| PT (1) | PT2812323T (zh) |
| RS (1) | RS55377B1 (zh) |
| SG (1) | SG11201404654SA (zh) |
| SI (1) | SI2812323T1 (zh) |
| TW (1) | TWI572593B (zh) |
| UA (1) | UA116627C2 (zh) |
| WO (1) | WO2013117288A1 (zh) |
| ZA (1) | ZA201406579B (zh) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2611504T3 (es) | 2012-03-07 | 2017-05-09 | Institute Of Cancer Research: Royal Cancer Hospital (The) | Compuestos de isoquinolin-1-ona 3-aril-5-sustituida y sus usos terapéuticos |
| US9505749B2 (en) | 2012-08-29 | 2016-11-29 | Amgen Inc. | Quinazolinone compounds and derivatives thereof |
| HUE030613T2 (en) | 2012-12-31 | 2017-05-29 | Cadila Healthcare Ltd | Substituted phthalazin-1 (2H) -one derivatives as selective inhibitors of poly (ADP-ribose) polymerase-1 |
| AU2014320149A1 (en) | 2013-09-11 | 2016-04-07 | Institute Of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| AU2014347126A1 (en) | 2013-11-07 | 2016-04-28 | Eli Lilly And Company | Pyrido[2,3-d]pyrimidin-4-one compounds as tankyrase inhibitors |
| CN106243088B (zh) | 2015-06-03 | 2019-01-04 | 广东东阳光药业有限公司 | 取代的哌嗪化合物及其使用方法和用途 |
| KR101777475B1 (ko) * | 2015-12-08 | 2017-09-11 | 에스티팜 주식회사 | 신규한 디히드로피라노피리미디논 유도체 및 이들의 용도 |
| WO2017156350A1 (en) | 2016-03-09 | 2017-09-14 | K-Gen, Inc. | Methods of cancer treatment |
| NZ749946A (en) | 2016-06-30 | 2023-11-24 | Yakult Honsha Kk | Novel compound or pharmaceutically acceptable salt thereof |
| CN108727302A (zh) * | 2017-10-23 | 2018-11-02 | 科迈化工股份有限公司 | 一种环保型n-叔丁基-2-苯并噻唑次磺酰胺（ns）合成工艺 |
| JP7288161B2 (ja) | 2017-12-27 | 2023-06-07 | 国立研究開発法人理化学研究所 | 新規ジヒドロキナゾリノン系化合物又はその薬理学的に許容される塩、及び細胞増殖阻害剤 |
| EP3733206A4 (en) * | 2017-12-27 | 2021-12-01 | Japanese Foundation For Cancer Research | ANTI-CANCER AGENT |
| US11760744B2 (en) | 2018-08-16 | 2023-09-19 | Genentech, Inc. | Fused ring compounds |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| PL194689B1 (pl) | 1996-02-13 | 2007-06-29 | Astrazeneca Uk Ltd | Pochodne chinazoliny, ich kompozycje farmaceutyczne oraz ich zastosowania |
| NZ331191A (en) | 1996-03-05 | 2000-03-27 | Zeneca Ltd | 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| NZ522074A (en) | 2000-05-31 | 2004-06-25 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| MXPA02012905A (es) | 2000-07-07 | 2004-07-30 | Angiogene Pharm Ltd | Derivados de colquinol como agentes de dano vascular.. |
| IL153325A0 (en) | 2000-07-07 | 2003-07-06 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors |
| AUPR201600A0 (en) * | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
| AUPR975601A0 (en) * | 2001-12-24 | 2002-01-31 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivatives |
| AUPS019702A0 (en) * | 2002-01-29 | 2002-02-21 | Fujisawa Pharmaceutical Co., Ltd. | Condensed heterocyclic compounds |
| NZ551680A (en) * | 2004-06-30 | 2010-02-26 | Janssen Pharmaceutica Nv | Quinazolinone derivatives as PARP inhibitors |
| ES2359931T3 (es) * | 2005-03-11 | 2011-05-30 | Merck Patent Gmbh | Tetrahidro- y dihidroquinazolinonas. |
| WO2008107478A1 (en) * | 2007-03-08 | 2008-09-12 | Janssen Pharmaceutica Nv | Quinolinone derivatives as parp and tank inhibitors |
| WO2011078143A1 (ja) | 2009-12-22 | 2011-06-30 | 塩野義製薬株式会社 | ピリミジン誘導体およびそれらを含有する医薬組成物 |
| WO2011111880A1 (ko) * | 2010-03-08 | 2011-09-15 | 주식회사 메디젠텍 | 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물 |
-
2013
- 2013-01-14 NZ NZ630170A patent/NZ630170A/en not_active IP Right Cessation
- 2013-01-14 AU AU2013218357A patent/AU2013218357B2/en active Active
- 2013-01-14 CN CN201380008647.2A patent/CN104093714B/zh active Active
- 2013-01-14 RS RS20160507A patent/RS55377B1/sr unknown
- 2013-01-14 EA EA201400879A patent/EA026611B1/ru not_active IP Right Cessation
- 2013-01-14 UA UAA201409705A patent/UA116627C2/uk unknown
- 2013-01-14 JP JP2014555963A patent/JP6116592B2/ja active Active
- 2013-01-14 PL PL13701703.4T patent/PL2812323T3/pl unknown
- 2013-01-14 DK DK13701703.4T patent/DK2812323T3/en active
- 2013-01-14 EP EP13701703.4A patent/EP2812323B1/en active Active
- 2013-01-14 KR KR1020147024967A patent/KR20140121477A/ko not_active Application Discontinuation
- 2013-01-14 PE PE2014001242A patent/PE20141823A1/es not_active Application Discontinuation
- 2013-01-14 HU HUE13701703A patent/HUE029717T2/en unknown
- 2013-01-14 CA CA2863991A patent/CA2863991C/en active Active
- 2013-01-14 BR BR112014019357A patent/BR112014019357A8/pt not_active Application Discontinuation
- 2013-01-14 SI SI201330228A patent/SI2812323T1/sl unknown
- 2013-01-14 WO PCT/EP2013/000078 patent/WO2013117288A1/en active Application Filing
- 2013-01-14 ES ES13701703.4T patent/ES2579980T3/es active Active
- 2013-01-14 US US14/378,009 patent/US9339503B2/en active Active
- 2013-01-14 MX MX2014009491A patent/MX349736B/es active IP Right Grant
- 2013-01-14 SG SG11201404654SA patent/SG11201404654SA/en unknown
- 2013-01-14 PT PT137017034T patent/PT2812323T/pt unknown
- 2013-02-08 TW TW102105039A patent/TWI572593B/zh not_active IP Right Cessation
- 2013-02-08 AR ARP130100401A patent/AR089944A1/es unknown
-
2014
- 2014-07-09 PH PH12014501581A patent/PH12014501581A1/en unknown
- 2014-07-30 CO CO14165918A patent/CO7020919A2/es unknown
- 2014-08-06 IL IL233984A patent/IL233984A/en active IP Right Grant
- 2014-08-07 CL CL2014002097A patent/CL2014002097A1/es unknown
- 2014-09-05 EC ECIEPI201417586A patent/ECSP14017586A/es unknown
- 2014-09-08 ZA ZA2014/06579A patent/ZA201406579B/en unknown
-
2015
- 2015-04-01 HK HK15103292.2A patent/HK1202551A1/zh not_active IP Right Cessation
-
2016
- 2016-06-24 HR HRP20160735TT patent/HRP20160735T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20160735T1 (hr) | Derivati tetrahidro-kinazolinona kao inhibitori tank i parp | |
| IL237011A0 (en) | Dihydropyridone p1 as factor xia inhibitors | |
| IL237012A0 (en) | Dihydropyridone p1 as factor xia inhibitors | |
| HK1210777A1 (zh) | 作為 抑制劑的喹唑酮衍生物 | |
| SI2920149T1 (sl) | Spojine 3-aminocikloalkila kot zaviralci receptorja ROR-gama-t in uporaba teh spojin | |
| ZA201409497B (en) | Tetrahydroquinazolinone derivatives as parp inhibitors | |
| SG11201500973WA (en) | Amino-quinolines as kinase inhibitors | |
| IL236138A0 (en) | Difluoro-hexahydro-cyclopentaoxazinil and difluoro-hexahydro-benzooxazinil as BACE1 inhibitors | |
| HK1209422A1 (zh) | 抑制劑 | |
| HK1212331A1 (zh) | 作為選擇性 抑制劑的 -甲酰氨基-異二氫吲哚酮衍生物 | |
| HK1209105A1 (zh) | 抑制劑 | |
| HK1209104A1 (zh) | 抑制劑 | |
| HK1201066A1 (zh) | 端錨聚合酶的吡喃並吡啶酮抑制劑 | |
| GB201223308D0 (en) | Enzyme inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20210110 |